Integrum (INTEG-B.ST) Stock Analysis & AI Equity Report
Integrum (INTEG-B.ST) overview
Integrum (INTEG-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Integrum reported revenue of SEK 91.1m and operating profit of SEK -42.4m; the year-end share price was 13.66 SEK and market capitalisation was SEK 291m. Integrum is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Integrum's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-18. Data will be refreshed during report generation.
About Integrum
Integrum AB develops and markets bone-anchored implant systems for amputees, centered on its OPRA implant system based on osseointegration. The company’s products are designed to connect prostheses directly to the skeleton for both upper and lower limb applications. It also supports surgeons and clinical partners involved in implant planning, surgery, and rehabilitation.
Generate the Integrum report
Integrum is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Integrum and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.